| HOME >> BIOLOGY >> TECHNOLOGY |
Also featured in the magazine is Professor Jeffrey L. Cummings, the Chair of Prana Biotechnology Research & Development Advisory Board. A world renowned authority on Alzheimer's disease Dr. Cummings' has authored 30 books and over 500 peer reviewed papers on the disease.
"We congratulate Professor Tanzi and Professor Cummings for their rock star achievements," said Geoffrey Kempler, Prana's Chairman and CEO. "We consider it a significant accomplishment that some of the most brilliant scientific minds are leading advocates of Prana and its strategy for the treatment of Alzheimer's disease."
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The
* For further information, and descriptions of the peer-reviewed journals, please visit the Company's web site at www.pranabio.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are no
'/>"/>
| SOURCE Prana Biotechnology Limited Copyright©2009 PR Newswire. All rights reserved |